Targeting RTK signaling pathways in cancer

Regad, T. ORCID: 0000-0003-4028-6368, 2015. Targeting RTK signaling pathways in cancer. Cancers, 7 (3), pp. 1758-1784. ISSN 2072-6694

[img]
Preview
Text
220867_PubSub2695_Regad.pdf

Download (840kB) | Preview

Abstract

The RAS/MAP kinase and the RAS/PI3K/AKT pathways play a key role in the regulation of proliferation, differentiation and survival. The induction of these pathways depends on Receptor Tyrosine Kinases (RTKs) that are activated upon ligand binding. In cancer, constitutive and aberrant activations of components of those pathways result in increased proliferation, survival and metastasis. For instance, mutations affecting RTKs, Ras, B-Raf, PI3K and AKT are common in perpetuating the malignancy of several types of cancers and from different tissue origins. Therefore, these signaling pathways became prime targets for cancer therapy. This review aims to provide an overview about the most frequently encountered mutations, the pathogenesis that results from such mutations and the known therapeutic strategies developed to counteract their aberrant functions.

Item Type: Journal article
Publication Title: Cancers
Creators: Regad, T.
Publisher: MDPI
Place of Publication: Basel
Date: 2015
Volume: 7
Number: 3
ISSN: 2072-6694
Identifiers:
NumberType
10.3390/cancers7030860DOI
Divisions: Schools > School of Science and Technology
Record created by: EPrints Services
Date Added: 09 Oct 2015 09:44
Last Modified: 09 Jun 2017 13:09
URI: https://irep.ntu.ac.uk/id/eprint/1962

Actions (login required)

Edit View Edit View

Views

Views per month over past year

Downloads

Downloads per month over past year